Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Interventions to improve hope and psychosocial outcomes in patients with advanced solid tumor cancer: A systematic review and meta-analysis.

Alanna Trees, Abigail Kaminsky, Rachel Hoover et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24100

e24100 Background: Hope is critical for individuals facing cancer, impacting quality of life, emotional well-being, and en...

The impact of human papillomavirus (HPV) vaccination on cervical cancer risk reduction in the US.

Sarah Phillips, Priti Bandi, Jessica Star et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22531

e22531 Background: High-risk human papillomavirus (HPV) causes most cervical cancers. Both HPV vaccination and cancer scre...

Comparative analysis of tirzepatide versus metformin and insulin in type 2 diabetes patients across the 13 most common cancers.

Viraj R. Shah, Shivam Singh, Nandhini Iyer et al. Jun 01, 2026 pp. 10508-10508 10.1200/jco.2026.44.16_suppl.10508

10508 Background: Emerging glucose-lowering therapies may influence cancer risk in patients with type 2 diabetes mellitus...

Incremental prognostic value of an AI-derived histology signature beyond the 21-gene recurrence score: A prospective-retrospective validation in TAILORx.

Magali Lacroix-Triki, Robert James Gray, Valentin Gaury et al. Jun 01, 2026 pp. 554-554 10.1200/jco.2026.44.16_suppl.554

554 Background: The 21-gene recurrence score (RS) is a foundational tool for risk-stratifying HR+/HER2- early breast cance...

Circulating tumor DNA monitoring for early detection of disease recurrence in bone/soft tissue sarcoma.

Maggie Yuxi Zhou, Nam Bui, Minggui Pan et al. Jun 01, 2026 pp. 11540-11540 10.1200/jco.2026.44.16_suppl.11540

11540 Background: Circulating tumor DNA (ctDNA) is a powerful, minimally invasive biomarker of treatment response and pati...

Maintenance therapy and treatment holiday in patients with unresectable/locally advanced/metastatic pancreatic cancer who did not progress after at least 2 months of first-line chemotherapy.

WonSeok William Choi, Jacob Matt Elkon Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16372

e16372 Background: Although the overall prognosis of metastatic pancreatic cancer remains poor, according to SEER database...

Modern Hodgkin lymphoma treatments to reduce second cancer risks: Influence of risk-adapted screening.

Aislinn Macklin-Doherty, David Cunningham, Ian Chau et al. Jun 01, 2026 pp. 7053-7053 10.1200/jco.2026.44.16_suppl.7053

7053 Background: Second primary malignancies (SPMs) are the leading cause of long-term treatment-related mortality in Hodg...

Nutritional anemia and risk of critical illness among hospitalized patients with head and neck cancer.

Alexandra Sueldo, Youjin Oh, Lucas Kuzmanic et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18131

e18131 Background: Patients with head and neck cancer frequently experience nutritional compromise related to tumor locati...

Association between pre-diagnostic upper endoscopy and metastatic gastric cancer at diagnosis among patients from high-risk groups.

Rohit Khullar, Xiaocen Zhang, Sonia Friedman Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23446

e23446 Background: Gastric cancer is frequently diagnosed at advanced stages in the United States. Although select high-ri...

Impact of immunotherapy on sotorasib toxicity in NSCLC: A real-world matched analysis.

Ansy Patel, Stephen L. Graziano, Deevyashali Parekh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16184

e16184 Background: Sotorasib is a standard targeted therapy for KRAS G12C-mutated...

Induction chemoimmunotherapy followed by hypofractionated radiotherapy and consolidation immunotherapy for locally advanced unresectable non–small cell lung cancer: A prospective phase II study.

Xiangzhi Zhu, Lijun Zhao, Ning Jiang et al. Jun 01, 2026 pp. 8037-8037 10.1200/jco.2026.44.16_suppl.8037

8037 Background: Concurrent chemoradiotherapy followed by consolidation immunotherapy is the standard treatment for unrese...

Association of acute kidney injury with in-hospital mortality and resource utilization among U.S. solid tumor hospitalizations: A National Inpatient Sample analysis, 2018–2022.

Carter Taysom, Ramaditya Srinivasmurthy, Riccesha Hattin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23163

e23163 Background: Acute kidney injury (AKI) is a common and clinically significant complication among patients hospitaliz...

Early indicators of prostate cancer risk in a community-based screening program in Lagos, Nigeria.

Ayodeji Oluwatobi Ojetunde, Moyinoluwa Opeyemi Akinwumi, Favour Okoye et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22503

e22503 Background: Community-based prostate health screening programs are important for early identification of men at ris...

Evaluation and appraisal of quality indicators for end-of-life cancer care in an African context.

Vivens Nsabimana, Jordana Avigad, Olive Mukeshimana et al. Jun 01, 2026 pp. 1517-1517 10.1200/jco.2026.44.16_suppl.1517

1517 Background: Population-based quality indicators (QIs) for end-of-life (EoL) cancer care are used to monitor and impro...

Intratumoral heterogeneity and genetic testing utilization in glioblastoma patients: A retrospective study at the University of Vermont Medical Center.

Leena Ziane, Shrey Patel, Oluwatosin Akintola Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14091

e14091 Background: Glioblastoma (GBM) is a primary malignant tumor characterized by intratumoral heterogeneity. Key biomar...

Development of an online bone marrow transplant (BMT) unit medical education platform for internal medicine (IM) residents: A pilot study.

Giuliana Giuseppina Berardi, Brianna Graham, Asya Varshavsky Yanovsky Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21000

e21000 Background: Studies demonstrate that less than 50% of Internal Medicine (IM) residents feel comfortable car...

Racial disparities in molecular testing among patients with early-onset metastatic pancreatic ductal adenocarcinoma.

Nadia Kirmani, Rania Abdusumad, Adhvaith Balakrishnan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13752

e13752 Background: Germline and somatic genetic testing are considered standard of care for patients with pancreatic ducta...

Functional binding of PD-1 ligands: Overcoming PD-L1 staining limitations to predict therapy response.

Bar Kaufman, Olga Radinsky, Adit Ben-Baruch et al. Jun 01, 2026 pp. 2581-2581 10.1200/jco.2026.44.16_suppl.2581

2581 Background: Immune-checkpoint blockade (ICB) targeting the PD-1/PD-L1 axis has improved outcomes across multiple mali...

Real-world outcomes in gastrointestinal cancer patients with targetable genomic alterations identified on serial liquid biopsy.

Linda Albusoul, Lauren Welch, Matthew Margolis et al. Jun 01, 2026 pp. 4238-4238 10.1200/jco.2026.44.16_suppl.4238

4238 Background: Precision oncology in gastrointestinal (GI) cancers relies on identifying targetable genomic alterations...

Do all patients really need hormonal screening before an adrenal biopsy?

Damien Urban, Yael Eshet, Sivan Lieberman et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23070

e23070 Background: Timely tissue diagnosis is critical in patients with suspected advanced cancer, particularly as many de...

Representation of rural oncology practices in quality certification programs: Insights from QOPI and CoC data.

Andrew Foster Armstrong, Collin Kray, Aidan Mayer Swenson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23291

e23291 Background: Quality certification programs like the ASCO Quality Oncology Practice Initiative (QOPI), focused on ch...

Association of Medicaid expansion with pre-diagnosis coverage continuity and 2-year overall survival in pediatric patients with blood cancer.

Rebecca Williamson Lewis, Sharon M. Castellino, Elyse Zhang et al. Jun 01, 2026 pp. 11033-11033 10.1200/jco.2026.44.16_suppl.11033

11033 Background: Continuous insurance coverage is critical for timely cancer diagnosis and treatment, yet many patients g...

Analysis of delta-like ligand 3 (DLL3) expression levels and characteristics of patients (pts) with advanced extrapulmonary neuroendocrine carcinomas (epNECs) from an ongoing phase I trial.

Valentina Gambardella, Martin Wermke, Yasutoshi Kuboki et al. Jun 01, 2026 pp. 2642-2642 10.1200/jco.2026.44.16_suppl.2642

2642 Background: Specific DLL3 expression on the surface of epNEC tumor cells makes it a promising therapeutic target, but...

Dysregulation of the insulin-like growth factor system in non–small cell lung cancer tissue and histologically normal lung tissue in patients with varying degrees of COVID-19 severity.

Dmitry A. Kharagezov, Elena M. Frantsiyants, Valeria Bandovkina et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20046

e20046 Background: The COVID-19 pandemic has created new challenges in oncology, particularly in relation to lung cancer....

Baseline immune and gut microbial–metabolic profiles associated with hepatic immune-related adverse events in lung cancer.

Man Sun, Dan Zang, Jun Chen Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20605

e20605 Background: Hepatic immune-related adverse events (HRAEs) are clinically significant toxicities of immune checkpoin...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page